BioLife and Kite Pharma are pleased to announce that they have entered into a 10 year supply agreement for BioLife’s CryoStor clinical grade freeze media for cells and tissues, which is embedded in Kite’s manufacturing process for KTE-C19, a CAR T cell therapy. Kite Pharma is currently in four clinical trials for various cancers.
Marc Better, Vice President, Product Sciences at Kite Pharma, noted, “Over the last several years we have worked to qualify and adopt CryoStor in our clinical manufacturing process. We are now securing long term supply continuity for this reagent as our cell therapy product candidate continues to progress through multiple clinical trials.”
BioLife is please to be a key supplier to the the emerging CAR T space. For more information or to read the full Press Release, please click here.
Menu
